"Progress in Amyloidosis Research: Where Are We Now?"

Presented by Jeffrey A. Zonder, MD - Professor from the Department of Oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine.

[@geribrinley]

Question - what is the "typical longevity" of taking tafamidis, for example. The charts all seem to go down eventually, but it appeared that the tafamidis stabilized after a period of time.

[@mselmaleh1]

😳👵